WELCOME TO MEDSHADOW. WE'VE UPDATED OUR LOOK!

Prescription Drug Advertising May Soon Come to Twitter

Prescription Drug Advertising May Soon Come to Twitter
Prescription Drug Advertising May Soon Come to Twitter
Last updated:

You’ve seen them in magazines, on television and on Internet websites. And pharmaceutical companies might soon be able to promote medications on a new medium: Twitter.

The FDA says it is investigating whether to allow drugs ads on social media platforms such as Twitter. If you’re wondering why the drug industry hasn’t tried ads on social media before, it’s because under FDA regulations, drugmakers need to provide benefit and risk information in a balanced fashion. And that’s nearly impossible to do with a 140-character limit on places like Twitter.

FDA Weighing Social Media Prescription Drug Advertising

The FDA has being weighing this kind of social media advertising since at least June 2014 when it issued guidance on how to present risk and benefit information for industry in a document titled “Internet/Social Media Platforms with Character Space Limitations.” The guidance also covers online paid search, which are sponsored links on search engines such as Google.

In the guidance at least, the FDA appears a bit hesitant to allow Twitter-esque advertising.

“For some products, particularly those with complex indications or extensive serious risks, character space limitations imposed by platform providers may not enable meaningful presentation of both benefit and risk…If an accurate and balanced presentation of both risks and benefits of a specific product is not possible within the constraints of the platform, then the firm should reconsider using that platform for the intended promotional message.”

However, in a notice posted on Nov. 7, the FDA now appears to be looking at ways to make Twitter advertising a reality. The agency is examining whether providing a link in a Twitter post that would open up into a new webpage with risk information can still provide a balanced view of benefits and risks.

To do this, the FDA is going to conduct a series of studies involving test subjects to see how well they comprehend and can recall risk information presented on fictitious drugs based on whether the risk information is in the ad or is contained in a link contained in the ad.

The FDA hypothesizes that those subjects who see substantive risk information in the communication itself rather than having to click on the link will have better recall and understanding of a drug’s risks.

DISCLAIMER: MedShadow provides information and resources related to medications, their effects, and potential side effects. However, it is important to note that we are not a substitute for professional medical advice, diagnosis, or treatment. The content on our site is intended for educational and informational purposes only. Individuals dealing with medical conditions or symptoms should seek guidance from a licensed healthcare professional, such as a physician or pharmacist, who can provide personalized medical advice tailored to their specific circumstances.

While we strive to ensure the accuracy and reliability of the information presented on MedShadow, we cannot guarantee its completeness or suitability for any particular individual's medical needs. Therefore, we strongly encourage users to consult with qualified healthcare professionals regarding any health-related concerns or decisions. By accessing and using MedShadow, you acknowledge and agree that the information provided on the site is not a substitute for professional medical advice and that you should always consult with a qualified healthcare provider for any medical concerns.

Was This Article Helpful?

Show Comments (0)
0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x